October 23, 2014 1:19 AM ET


Company Overview of Oxford BioTherapeutics Limited

Company Overview

Oxford BioTherapeutics Limited is engaged in the development of antibody-based cancer drugs for the treatment of cancer. It offers therapeutic antibodies and diagnostics. The company also provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies. It has strategic partnerships with Seattle Genetics Inc., Medarex Inc., Biosite Inc., Amgen Inc., and GlaxoSmithKline; and a strategic alliance with A. Menarini Industrie Farmaceutiche Riunite Srl. Oxford BioTherapeutics Limited was formerly known as Oxford Genome Sciences (UK) Limited and changed its name to Oxford BioTherapeutics Limited. in December 2008. The company was incorporated in 2003 and ...

94a Milton Park


Oxon,  OX14 4RY

United Kingdom

Founded in 2003


44 1235 861 770


44 1235 861 771

Key Executives for Oxford BioTherapeutics Limited

Chief Operations Officer and Executive Director
Senior Vice President of Protein Sciences
Senior Vice President of Non-Clinical Development
Head of Clinical Development
Compensation as of Fiscal Year 2014.

Oxford BioTherapeutics Limited Key Developments

Oxford BioTherapeutics Appoints Eugen Leo as Head of Clinical Development

Oxford BioTherapeutics announced the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development. Dr. Leo brings substantial clinical development experience of targeted and first-in-class molecules, as well as extensive translational research experience, and will be responsible for driving the Company's attractive pipeline of ADCs into clinical development. He previously worked at Micromet, where he held several positions with increasing seniority and was instrumental in developing the company's BiTE antibody platform to clinical proof-of-concept, which received breakthrough therapy designation by FDA on July 1, 2014.

Oxford BioTherapeutics Appoints Keith E Wilson as Chief Scientific Officer

Oxford BioTherapeutics announced the appointment of Dr. Keith E Wilson as Chief Scientific Officer. Dr. Wilson joins from AbbVie where he was the company’s Global Leader for Antibody Drug Conjugates. Dr. Keith E Wilson brings to Oxford BioTherapeutics over 20 years’ experience of life sciences research and development, specializing in oncology and immunology. He has extensive experience of developing and executing novel discovery, clinical and portfolio strategies, as well as providing executive-level support for corporate and business development activities. In his most recent role, he was Director, Biologics Technology and Global Leader, Antibody Drug Conjugates at AbbVie, where he was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team.

Oxford BioTherapeutics Limited Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014

Oxford BioTherapeutics Limited Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 . Venue: London, United Kingdom.

Similar Private Companies By Industry

Company Name Region
Orthogem Ltd. Europe
Lab M Limited Europe
Oxford Biomedica (UK) Limited Europe
IC-Vec Ltd. Europe
ADC Biotechnology Ltd Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oxford BioTherapeutics Limited, please visit www.oxfordbiotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.